Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population
- 2 July 2008
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 300 (1), 51-59
- https://doi.org/10.1001/jama.300.1.51
Abstract
Context Mortality among human immunodeficiency virus (HIV)–infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population. Objective To evaluate changes in the mortality gap between HIV-infected individuals and the general uninfected population. Design, Setting, and Population Mortality following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts (CASCADE) was compared with expected mortality, calculated by applying general population death rates matched on demographic factors. A Poisson-based model adjusted for duration of infection was constructed to assess changes over calendar time in the excess mortality among HIV-infected individuals. Data pooled in September 2007 were analyzed in March 2008, covering years at risk 1981-2006. Main Outcome Measure Excess mortality among HIV-infected individuals compared with that of the general uninfected population. Results Of 16 534 individuals with median duration of follow-up of 6.3 years (range, 1 day to 23.8 years), 2571 died, compared with 235 deaths expected in an equivalent general population cohort. The excess mortality rate (per 1000 person-years) decreased from 40.8 (95% confidence interval [CI], 38.5-43.0; 1275.9 excess deaths in 31 302 person-years) before the introduction of highly active antiretroviral therapy (pre-1996) to 6.1 (95% CI, 4.8-7.4; 89.6 excess deaths in 14 703 person-years) in 2004-2006 (adjusted excess hazard ratio, 0.05 [95% CI, 0.03-0.09] for 2004-2006 vs pre-1996). By 2004-2006, no excess mortality was observed in the first 5 years following HIV seroconversion among those infected sexually, though a cumulative excess probability of death remained over the longer term (4.8% [95% CI, 2.5%-8.6%] in the first 10 years among those aged 15-24 years). Conclusions Mortality rates for HIV-infected persons have become much closer to general mortality rates since the introduction of highly active antiretroviral therapy. In industrialized countries, persons infected sexually with HIV now appear to experience mortality rates similar to those of the general population in the first 5 years following infection, though a mortality excess remains as duration of HIV infection lengthens.This publication has 19 references indexed in Scilit:
- Survival following HIV infection of a cohort followed up from seroconversion in the UKAIDS, 2008
- Survival of Persons with and without HIV Infection in Denmark, 1995–2005Annals of Internal Medicine, 2007
- Variation in relative survival of thyroid cancers in Europe: Results from the analysis on 21 countries over the period 1983–1994 (EUROCARE-3 study)European Journal of Cancer, 2006
- Mortality in Patients With Successful Initial Response to Highly Active Antiretroviral Therapy Is Still Higher Than in Non-HIV-Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss populationAIDS, 2004
- Regression models for relative survivalStatistics in Medicine, 2003
- The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysisAnnals of Oncology, 2003
- Determinants of survival following HIV-1 seroconversion after the introduction of HAARTThe Lancet, 2003
- Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general populationThe Lancet, 2003
- Decline in the AIDS and death rates in the EuroSIDA study: an observational studyThe Lancet, 2003